In a defeat for one of the biggest U.S. drug makers, the U.S. Trade Representative has decided not to add Canada to its “Priority Watch” list of countries that fail to sufficiently protect and enforce patent rights. The agency’s decision comes despite a recent lobbying effort in Washington by Eli Lilly & Co.,